Dr. Blank on Personalizing Neoadjuvant Therapy in Stage III Macroscopic Melanoma

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses ongoing research efforts to personalize neoadjuvant therapy in stage III macroscopic melanoma. 

Many ​smaller neoadjuvant studies with similar designs have been conducted in this space, says Blank​. ​However, the next step is to define the responders and non-responders, ​potentially through RNA signature ​assessment.

Ultimately, any differences or overlaps that are found could suggest the best course of treatment for individual patient​s, Blank explains. 

In comparison with other malignancies, melanoma appears to be leading the way in terms of neoadjuvant therapy research, Blank concludes.